ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2276

Risk of Hemorrhagic Strokes in Patients with Adenosine Deaminase 2 Deficiency

Patrycja M. Hoffmann1, Amanda Ombrello1, Deborah L. Stone2, Dean Follmann3, Karyl Barron4, Anne Jones5, Tina Romeo1, Camilo Toro6, Ariane Soldatos7, Arielle Hay8, Qing Zhou9, Ivona Aksentijevich10 and Daniel L. Kastner5, 1NHGRI, National Institutes of Health, Bethesda, MD, 2Inflammatory Disease Section, NHGRI/NIH, Bethesda, MD, 3NIAID, Bethesda, MD, 4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 5Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 6NIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 7NINDS, National Institutes of Health, Bethesda, MD, 8Nicklaus Children’s Hospital, Miami, FL, 9China, 10Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Aspirin and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive condition characterized by recurrent fevers, early-onset ischemic strokes, livedo racemosa, polyarteritis nodosa, portal hypertension, immune deficiencies, and cytopenias. Additionally, several patients with DADA2 have had hemorrhagic strokes. DADA2 is caused by biallelic loss-of-function mutations in the ADA2 gene (formerly known as CECR1), resulting in very low ADA2 levels in the blood, vasculopathy, and M1 skewing of macrophage differentiation. The use of tumor necrosis factor (TNF) inhibitors has significantly reduced the risk of recurrent stroke. In this abstract, we report two TNF-inhibitor naïve cases who cumulatively developed three spontaneous hemorrhagic strokes on no anticoagulants/antiplatelets. Additionally, we examine the safety of anticoagulants/antiplatelets in patients with DADA2.

Methods: A single center study evaluated 24 patients who had biallelic germline mutations in the ADA2 gene. Patients were subdivided into those with a history of hemorrhagic stroke versus those without. We then identified the patients with hemorrhagic strokes on no anticoagulant/antiplatelet treatment, ASA alone, and other anticoagulants/antiplatelets versus patients without hemorrhagic stroke on no anticoagulant/antiplatelet treatment, ASA alone, and other anticoagulants/antiplatelets. None of the patients had been on TNF inhibitors at the time of the analysis. The primary outcome measure was to determine occurrence of hemorrhagic strokes in patients with DADA2 and if there is increased risk on anticoagulant/antiplatelet treatment.

Results: Among the 24 patients, 6 (25%) had hemorrhagic strokes and of those 1 was on ASA alone, 3 were on anticoagulants/antiplatelets, and 2 were on no anticoagulants/antiplatelets. The remaining 18 patients did not have a hemorrhagic stroke and of those, 8 were on ASA alone, 3 were on anticoagulants/antiplatelets, and 7 were on no anticoagulants/antiplatelets. The probability of a hemorrhagic stroke following anticoagulant/antiplatelet therapy is 4/13 (31%) while the probability of a hemorrhagic stroke following no such therapy is 2/11 (18%). A Fisher’s exact test showed a p-value of 0.6494 (NS). The prevalence of patients with hemorrhagic strokes on ASA alone, no anticoagulant/antiplatelets, and on anticoagulants/antiplatelets were 1:6, 2:6, 3:6 respectively. A Fisher’s exact test showed a p-value of 0.263 (NS).

Conclusion: In patients with DADA2, we have shown that there is a strong baseline risk of hemorrhagic strokes as evidenced by the two patients who cumulatively suffered three hemorrhagic strokes on no anticoagulant or antiplatelet treatment. The risk of hemorrhagic stroke was not significantly increased on anticoagulants/antiplatelet agents possibly due to the small sample size. However, given the baseline risk of hemorrhagic stroke in DADA2, and the (non-significant) increase in that risk on anticoagulants and antiplatelet agents, such agents should probably not be used in DADA2 except under extraordinary circumstances.


Disclosure: P. M. Hoffmann, None; A. Ombrello, None; D. L. Stone, None; D. Follmann, None; K. Barron, None; A. Jones, None; T. Romeo, None; C. Toro, None; A. Soldatos, None; A. Hay, None; Q. Zhou, None; I. Aksentijevich, None; D. L. Kastner, None.

To cite this abstract in AMA style:

Hoffmann PM, Ombrello A, Stone DL, Follmann D, Barron K, Jones A, Romeo T, Toro C, Soldatos A, Hay A, Zhou Q, Aksentijevich I, Kastner DL. Risk of Hemorrhagic Strokes in Patients with Adenosine Deaminase 2 Deficiency [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/risk-of-hemorrhagic-strokes-in-patients-with-adenosine-deaminase-2-deficiency/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-hemorrhagic-strokes-in-patients-with-adenosine-deaminase-2-deficiency/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology